Skip to content
Screener

Ultragenyx Pharmaceutical RARE Other Non-Current Assets

Other Non-Current Assets at other companies

Eli Lilly logo
Eli LillyLLY
$7.48B+20.2%
Amgen logo
AmgenAMGN
$12.98B+17.7%
Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
$116.54M-11.8%
Arrowhead Research logo
Arrowhead ResearchARWR
$4.89M+272%
Zevra Therapeutics, Inc. logo
Zevra Therapeutics, Inc.ZVRA
$3K-98.6%
Regenxbio logo
RegenxbioRGNX
$5.9M+214%

Other financials

Income statement

See full
Revenue$214.0M+28.1%
Operating income-$75.0M+30.6%
Net income-$92.0M+20.0%
EPS (diluted)-$0.90+23.1%

Balance sheet

See full
Cash & equivalents$125.0M-29.0%
Total debt$36.0M-10.8%
Total equity-$291.0M-293%
Total assets$1.3B-3.2%

Cash flow

See full
Operating cash flow-$97.0M+11.0%
CapEx$1.0M-66.7%
Free cash flow-$98.0M+12.5%

Valuation

See full
Market cap$2.55B-5.8%
P/S3.6×-0.9×

Profitability

See full
Gross margin97.2%—
Operating margin-73.6%-7.3pp
Net margin-81.7%-4.9pp
FCF margin-68.2%-1.7pp

Returns & leverage

See full
Return on equity-325.6%+36.9pp
Debt / equity3.7×—
Current ratio1.7×-0.7×

Where this comes from

Reported directly by Ultragenyx Pharmaceutical in its filing.

Tagged under the XBRL concept us-gaap:OtherAssetsNoncurrent.

The source filing: Ultragenyx Pharmaceutical’s 10-Q, filed August 5, 2026.

Filed
Aug 4, 2026, 8:00 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-333233
Line itemJune 30, 2026December 31, 2025
Marketable securities14457
Intangible assets, net172176
Goodwill4444
Other assets6360
Total assets$1,264$1,532
LIABILITIES, NONCONTROLLING INTEREST AND STOCKHOLDERS' EQUITY (DEFICIT)
Current liabilities:
Accounts payable$39$31

Item 1. Financial Statements

FAQ

What is Ultragenyx Pharmaceutical's other non-current assets?
Ultragenyx Pharmaceutical (RARE) reported other non-current assets of $63M in Q2 2026.
How has Ultragenyx Pharmaceutical's other non-current assets changed year-over-year?
Ultragenyx Pharmaceutical's other non-current assets increased by 4.8% year-over-year, from $60.12M to $63M.
What is the long-term trend for Ultragenyx Pharmaceutical's other non-current assets?
Over 5 years (2020 to 2025), Ultragenyx Pharmaceutical's other non-current assets has grown at a 46.8% compound annual growth rate (CAGR), from $8.81M to $60M.
What does other non-current assets mean?
Long-term assets not classified in specific categories — a catch-all for miscellaneous non-current assets.

Ask your AI about Ultragenyx Pharmaceutical's other non-current assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude